Arecor Therapeutics PLC
LSE:AREC
Intrinsic Value
Arecor Therapeutics Plc is a biopharmaceutical company that targets improving patient care by bringing medicines to market through the enhancement of existing therapeutic products. [ Read More ]
The intrinsic value of one AREC stock under the Base Case scenario is 368.98 GBX. Compared to the current market price of 137.5 GBX, Arecor Therapeutics PLC is Undervalued by 63%.
Valuation Backtest
Arecor Therapeutics PLC
Run backtest to discover the historical profit from buying and selling AREC stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Arecor Therapeutics PLC
| Current Assets | 16.1m |
| Cash & Short-Term Investments | 8.2m |
| Receivables | 5.9m |
| Other Current Assets | 1.9m |
| Non-Current Assets | 4.1m |
| PP&E | 720k |
| Intangibles | 3.3m |
| Other Non-Current Assets | 48k |
| Current Liabilities | 6.4m |
| Accounts Payable | 2.8m |
| Accrued Liabilities | 1.6m |
| Other Current Liabilities | 2m |
| Non-Current Liabilities | 547k |
| Long-Term Debt | 51k |
| Other Non-Current Liabilities | 496k |
Earnings Waterfall
Arecor Therapeutics PLC
|
Revenue
|
3.4m
GBP
|
|
Operating Expenses
|
-13.7m
GBP
|
|
Operating Income
|
-10.4m
GBP
|
|
Other Expenses
|
936k
GBP
|
|
Net Income
|
-9.4m
GBP
|
Free Cash Flow Analysis
Arecor Therapeutics PLC
AREC Profitability Score
Profitability Due Diligence
Arecor Therapeutics PLC's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
Arecor Therapeutics PLC's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
AREC Solvency Score
Solvency Due Diligence
Arecor Therapeutics PLC's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Score
Arecor Therapeutics PLC's solvency score is 60/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AREC Price Targets Summary
Arecor Therapeutics PLC
According to Wall Street analysts, the average 1-year price target for AREC is 480.42 GBX with a low forecast of 407.03 GBX and a high forecast of 565.95 GBX.
Shareholder Return
AREC Price
Arecor Therapeutics PLC
| Average Annual Return | 12.65% |
| Standard Deviation of Annual Returns | 74.45% |
| Max Drawdown | -71% |
| Market Capitalization | 42.1m GBX |
| Shares Outstanding | 30 627 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Arecor Therapeutics Plc is a biopharmaceutical company that targets improving patient care by bringing medicines to market through the enhancement of existing therapeutic products. The firm targets improving patient care by bringing medicines to market through the existing therapeutic products. The company partners with global pharmaceutical and biotechnology companies to apply the Arestat technology to their products under a technology licensing model. These products can be at any stage in development from early phase clinical development through to products that are already on the market. The areas of applications of the technology are biologicals, biosimilars, therapeutic vaccines and therapeutic peptides.
Contact
IPO
Employees
Officers
The intrinsic value of one AREC stock under the Base Case scenario is 368.98 GBX.
Compared to the current market price of 137.5 GBX, Arecor Therapeutics PLC is Undervalued by 63%.
You don't have any saved screeners yet
